Guidance, NICE advice and quality standards in development | Guidance

Showing 21 to 30 of 388

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]	Technology appraisal guidance	TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]	Technology appraisal guidance	TBC
Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]	Technology appraisal guidance	TBC
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]	Technology appraisal guidance	TBC
Atogepant for treating migraine [ID6615]	Technology appraisal guidance	30 June 2026
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]	Technology appraisal guidance	TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]	Technology appraisal guidance	TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]	Technology appraisal guidance	TBC